Promoting Equity and Access to MASLD Care

Nov 09 2025
Convention Center: Room 146A, Level 1
11:00 AM - 12:30 PM

World Class Speakers

Zobair M Younossi, MD, MPH, FAASLD
Abstract Presenter

Zobair M Younossi, MD, MPH, FAASLD
Arpan Mohanty, MBBS, MSc
Moderator

Arpan Mohanty, MBBS, MSc

Boston University Chobanian and Avedisian School of Medicine
Nitzan C Roth, MD, PhD
Moderator

Nitzan C Roth, MD, PhD

Northwell and Zucker School of Medicine at Hofstra/Northwell

Description

This session covers epidemiologic trends and social determinants of health that affect access to MASLD care.  

Journey Maps

Presentations

11:00 AM - 11:15 AM
Aug 06 2026
Convention Center - Room 146A, Level 1

Temporal Trends and Geographic Disparities in NAFLD Including Cirrhosis Across the United States, 1990–2021 

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health
11:15 AM - 11:30 AM
Aug 06 2026
Convention Center - Room 146A, Level 1

Explanatory Models of Weight and Liver Disease Among Patients with MASLD: A Qualitative Study

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health
11:30 AM - 11:45 AM
Aug 06 2026
Convention Center - Room 146A, Level 1

Double Trouble: A 25-Year Nationwide Analysis of Chronic Liver Disease in the Era of Metabolic Syndrome

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health
11:45 AM - 12:00 PM
Aug 06 2026
Convention Center - Room 146A, Level 1

Structural Determinants of Preventable MASLD-Related Premature Liver Mortality Across U.S. Counties: A Nationwide Ecological Analysis (2010–2020)

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health
12:00 PM - 12:15 PM
Aug 06 2026
Convention Center - Room 146A, Level 1

Racial/ethnic and Socioeconomic Disparities in Steatotic Liver Disease: The Multi-Ethnic Study of Atherosclerosis

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health
12:15 PM - 12:30 PM
Aug 06 2026
Convention Center - Room 146A, Level 1

Older Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Have Higher Rates of Lean MASLD and More Advanced Fibrosis but Better Health Related Quality of Life (HRQL)

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
Global
MASLD
Public Health

Objectives

  • Analyze structural and social determinants of health that affect disparities in MASLD outcomes.
  • Review strategies to promote equity in MASLD care
  • Analyze structural and social determinants of health that affect disparities in MASLD management.